United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $593.17, for a total transaction of $5,931,700.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $11,196,676.92. The trade was a 34.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total transaction of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00.

United Therapeutics Stock Down 1.0%

Shares of NASDAQ:UTHR opened at $564.81 on Friday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $607.89. The stock has a market cap of $24.76 billion, a PE ratio of 20.24, a P/E/G ratio of 1.66 and a beta of 0.75. The business has a 50 day moving average of $504.78 and a 200-day moving average of $477.55.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.19 earnings per share. Equities research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase‑3 Tyvaso (IPF) results met the study’s key endpoint, a material clinical success that supports revenue upside and longer‑term product expansion for United Therapeutics. This is the primary bullish catalyst behind the recent run‑up. United Therapeutics Is Up After Positive Tyvaso Data
• Positive Sentiment: Multiple sell‑side analysts have reacted favorably: HC Wainwright keeps a Buy and $660 target while tweaking quarterly EPS estimates (raising Q3, trimming Q1/Q2 modestly), and other brokers issued bullish notes/upgrades — supporting a higher near‑term valuation band. HC Wainwright Analyst Says Stock Expected to Rise
• Neutral Sentiment: Options activity is unusually high, suggesting traders are positioning around recent news and earnings risk; this can amplify intraday moves but is not a directional fundamental change. United Therapeutics Target of Unusually High Options Trading
• Neutral Sentiment: Coverage pieces and valuation analysis are appearing (assessments of Tyvaso’s impact on valuation); these shape investor expectations but don’t alter the underlying clinical win. Assessing United Therapeutics Valuation After Tyvaso Results
• Negative Sentiment: Insider selling: CEO Martine Rothblatt, EVP Paul Mahon and CFO James Edgemond all sold multi‑thousand share blocks in late March/early April (sales executed under Rule 10b5‑1 plans). The size and timing of these sales (millions of dollars each) can be interpreted as near‑term negative pressure or signal profit‑taking despite being pre‑arranged. Rothblatt SEC Filing (Example)

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on UTHR shares. UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. HC Wainwright upped their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday. Wells Fargo & Company raised their price target on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Cantor Fitzgerald lifted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, Royal Bank Of Canada boosted their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $586.00.

Institutional Trading of United Therapeutics

Large investors have recently modified their holdings of the stock. Torren Management LLC bought a new stake in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the period. Entrust Financial LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at approximately $31,000. Wilmington Savings Fund Society FSB raised its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. bought a new stake in shares of United Therapeutics during the 4th quarter worth approximately $48,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.